2002, Drug Development and Hospitals

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2002

Drug Development

Hospitals

Panel urges FDA to remove warnings on hormonal menopause therapy

BioPharma Dive

JULY 18, 2025

The study was stopped early in 2002 after researchers observed an increased risk of breast cancer and heart disease. During the meeting, Rachel Rubin, an assistant clinical professor in urology at Georgetown University Hospital and an adviser to Let’s Talk Menopause, urged the FDA to remove the box label.

Labelling

Labelling Drug Pricing Vaccines Medical Schools

Understanding the evidence used in drug product withdrawals

European Pharmaceutical Review

DECEMBER 14, 2023

Between 1999 and 2001, it supported 17 percent of withdrawals, between 2002 and 2011, it supported 26 percent of withdrawals and by 2012 to 2016, 80 percent of withdrawals were supported by observational studies (cohort, case-control, or other epidemiologic design). Meta-analyses contributed least frequently (31.4

Medical Records

Medical Records Vaccines Hospitals Drug Development

Pharmacist Digest

Panel urges FDA to remove warnings on hormonal menopause therapy

Understanding the evidence used in drug product withdrawals

Stay Connected